Impact ledger
Bristol-Myers Squibb Company (BMY)
17 events mapped to this ticker since 2026-06-12.
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-15 | Event | Increased competitive pressure in the oncology market from JNJ's enhanced pipeline. | watch | 1-5y | 0.30 |
| 2026-07-06 | Event | Increased competitive landscape in oncology, particularly in novel mechanisms of action. Could influence BMY's future R&D and M&A decisions. | watch | 1-5y | 0.30 |
| 2026-07-06 | Event | Increased competitive pressure in the oncology market, particularly in novel mechanisms of action. May prompt similar strategic moves. | watch | 1-3m | 0.30 |
| 2026-06-29 | Event | The reference to the MyoKardia acquisition, while historical, serves as a reminder of BMY's past M&A strategy. The success or failure of integrating MyoKardia's assets and pipeline (e.g., mavacamten, now Camzyos) would have long-term implications for BMY's revenue growth and profitability. The appoi | watch | 1-5y | 0.30 |
| 2026-06-26 | Event | Partnership revenue/royalty potential from nivolumab (Opdivo) sales in combination therapy. | watch | 1-3m | 0.20 |
| 2026-06-26 | Event | Competitive landscape in advanced melanoma treatment. | watch | 1-3m | 0.10 |
| 2026-06-23 | Event | Increased competition in the I&I therapeutic area, potential for talent migration, and a benchmark for investor sentiment towards innovative biotech. | watch | 1-3m | 0.20 |
| 2026-06-23 | Event | While a large pharmaceutical company, increased funding for smaller, innovative biotech firms like Odyssey could lead to more rapid development of competing therapies, potentially impacting future M&A targets or competitive landscape. | watch | 3-12m | 0.15 |
| 2026-06-23 | Event | Potential for future competition or collaboration in the lung cancer treatment market, specifically concerning PD-1/PD-L1 inhibitors. | watch | 3-12m | 0.20 |
| 2026-06-22 | Event | Similar to Merck, Bristol-Myers Squibb has a significant presence in PD-1/PD-L1 inhibitors (e.g., Opdivo). This patent could influence future competitive or collaborative strategies in lung cancer combination therapies. | watch | 3-12m | 0.10 |
| 2026-06-22 | Event | Potential future competition or partnership opportunities in the PD-1/PD-L1 inhibitor market for lung cancer. | watch | 3-12m | 0.10 |
| 2026-06-22 | Event | Potential future competition or partnership opportunities in the lung cancer treatment market, specifically concerning PD-1/PD-L1 inhibitors. | watch | 1-5y | 0.10 |
| 2026-06-22 | Event | Similar to Merck, potential future competition or partnership opportunities. Bristol-Myers Squibb's Opdivo (nivolumab) is another prominent PD-1 inhibitor. | watch | 1-5y | 0.10 |
| 2026-06-17 | Event | Potential for increased sales of checkpoint inhibitors (e.g., Opdivo) if ELI-002 7P is approved and used in combination therapies. | Bullish | 3-12m | 0.08 |
| 2026-06-17 | Event | Potential competitive pressure in the oncology market, specifically for pancreatic cancer treatments, if avutometinib progresses. | watch | 3-12m | 0.20 |
| 2026-06-12 | Event | Direct impact of cost-cutting initiatives on profitability and capital allocation strategy. Dividend sustainability is a key investor concern. | mixed | 1-3m | 0.70 |
| 2026-06-12 | Event | Potential competitive pressure in the broader hematology or autoimmune disease treatment markets, depending on the mechanism of action and future indications of HUTCHMED's drug. | watch | 1-5y | 0.20 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for BMY, start a trial or view the BMY entity page.